Glioblastoma Clinical Trials in New York, New York

18 studies are recruiting for glioblastoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

    This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or gliosarcoma that can be removed by surgery (resectable) and that is growing, spr…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    2 in total
    Run by
    Jonsson Comprehensive Cancer Center

    See if you can join NCT07089641 on ClinicalTrials.gov

  2. Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

    The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the bloo…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Weill Cornell Medicine, New York, New York
    Locations
    56 in total
    Run by
    CarThera

    See if you can join NCT05902169 on ClinicalTrials.gov

  3. Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

    The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    11 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06934889 on ClinicalTrials.gov

  4. INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

    This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    12 in total
    Run by
    David Reardon, MD

    See if you can join NCT02977780 on ClinicalTrials.gov

  5. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

    This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center, New York, New York
    Locations
    102 in total
    Run by
    NovoCure GmbH

    See if you can join NCT06556563 on ClinicalTrials.gov

  6. A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

    Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnose…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai, New York, New York
    Locations
    63 in total
    Run by
    Global Coalition for Adaptive Research

    See if you can join NCT03970447 on ClinicalTrials.gov

  7. Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

    The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to t…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    New York University Langone's Perlmutter Cancer Institute, New York, New York
    Locations
    2 in total
    Run by
    Baptist Health South Florida

    See if you can join NCT06991101 on ClinicalTrials.gov

  8. A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

    This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high gra…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Locations
    3 in total
    Run by
    Tetragon Biosciences Ltd

    See if you can join NCT07464925 on ClinicalTrials.gov

  9. Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

    The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study is evaluating an experimental treatment for glioblastoma th…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    New York Langone, New York, New York
    Locations
    11 in total
    Run by
    Alpheus Medical, Inc.

    See if you can join NCT07225621 on ClinicalTrials.gov

  10. Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT02861898 on ClinicalTrials.gov

  11. Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

    The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherap…

    Stage
    Phase 1
    Ages
    18 to 74
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT03213002 on ClinicalTrials.gov

  12. Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

    Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT05271240 on ClinicalTrials.gov

  13. Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

    This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT05954858 on ClinicalTrials.gov

  14. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

    This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT05979064 on ClinicalTrials.gov

  15. Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

    Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Lenox Hill Brain Tumor Center, New York, New York
    Run by
    Northwell Health

    See if you can join NCT02800486 on ClinicalTrials.gov

  16. Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

    The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06058988 on ClinicalTrials.gov

  17. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, New York, New York
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  18. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

    The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Medical Center - Herbert Irving Pavilion, New York, New York
    Locations
    8 in total
    Run by
    Orbus Therapeutics, Inc.

    See if you can join NCT05879367 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.